Immunoprecise Antibodies Ltd reports results for the quarter ended October 31 - Earnings Summary

Mindwalk Holdings

10/12/2024 14:32

* Immunoprecise Antibodies Ltd  IPA.OQ  reported a quarterly
adjusted loss of 9 cents​​ per share for the quarter ended
October 31, higher than the same quarter last year, when the
company reported EPS of -10 cents.  The mean expectation of
two analysts for the quarter was for a loss of 9 cents per
share. Wall Street expected results to range from -12 cents
to -7 cents per share.
    * Revenue fell 0.4% to C$6.13 million from a year ago;
analysts
expected C$6.44 million. 
    * Immunoprecise Antibodies Ltd's reported EPS for the
quarter was
a loss of 9 cents​.
    * The company reported a quarterly loss of C$2.55 million.
    * Immunoprecise Antibodies Ltd shares had fallen by 34.3%
this
quarter and lost 75.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 26.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Immunoprecise
Antibodies Ltd is $6.00 
This summary was machine generated from LSEG data December 10 at
02:31 p.m. UTC. ​All figures in Canadian dollars unless
otherwise stated. (For questions concerning the data in this
report, contact Estimates.Support@lseg.com. For any other
questions or feedback, contact
RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Oct. 31 2024      -0.09          -0.09          Met
 Jul. 31 2024      -0.11          -0.15          Missed
 Apr. 30 2024      -0.11          -0.11          Met
 Jan. 31 2024      -0.10          -0.11          Missed